FACT-Lung: Functional Assessment of Cancer Therapy—Lung
Functional Assessment of Cancer Therapy—Lung · Also known as: FACT-L
The FACT-Lung (FACT-L) is a lung-cancer-specific quality-of-life measure that combines a 27-item general cancer assessment with a 7-item lung cancer subscale. Developed by Cella et al. in 1995, it quantifies physical, emotional, social, and functional well-being specifically relevant to lung cancer patients. It is widely used in clinical trials and practice to assess treatment impact and symptom burden.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
FACT-Lung is indicated for patients with any stage of lung cancer (NSCLC, SCLC) undergoing active treatment or surveillance. Primary uses are clinical trials assessing treatment efficacy and toxicity, oncology clinical practice (baseline and periodic monitoring), and comparative effectiveness research. It is NOT designed for screening or diagnostic purposes. Particularly valuable when treatment decisions involve trade-offs between survival and QoL (e.g., chemotherapy toxicity vs. symptom control). Lung-specific subscale makes it preferable to generic instruments when respiratory symptoms are a key concern.
Strengths & limitations
- Lung-specific subscale directly captures dyspnea, cough, and other respiratory concerns unique to lung cancer, beyond generic cancer items.
- Dual-layer design (generic core + disease-specific extension) allows separate assessment of common cancer vs. lung-specific burden; useful for comparative trial analysis.
- Extensive validation in large, diverse lung cancer populations (NSCLC, SCLC, all stages); published MCID estimates support interpretation.
- Public domain (no licensing fees); readily available in multiple languages and modalities (paper, electronic, online).
- Established use in major clinical trials and FDA submissions; high clinical credibility and regulatory acceptance.
- LCS subscale (7 items) is relatively brief; may lack granularity for detailed respiratory symptom profiling in advanced lung disease.
- FACT-G core assumes general cancer relevance; some generic items may be less salient for early-stage or very advanced patients.
- No built-in performance status or disease activity measures; complementary clinical data (ECOG, imaging) needed for full context.
- Ceiling effects reported in some populations (e.g., early-stage post-surgical patients with excellent recovery), limiting sensitivity to minor improvements.
Frequently asked
Can FACT-Lung be used in early-stage NSCLC post-surgery?
Yes. FACT-Lung is validated across all lung cancer stages and treatments. Post-surgical scores often recover toward baseline within 6–12 months. Serial measurement is more informative than single baseline score for detecting clinically meaningful change in surgical recovery QoL.
What is the difference between FACT-L and EORTC QLQ-LC13?
FACT-L (34 items: 27 FACT-G core + 7 lung subscale) emphasizes general cancer plus lung-specific concerns; total range 0–136. EORTC QLQ-LC13 (13 lung-specific items added to QLQ-C30 core) is more symptom-focused, with dedicated dyspnea, cough, and hemoptysis items. EORTC is more prevalent in Europe; FACT-L more common in North America. Both are valid; choice depends on trial coordination and regional preference.
Is a MCID of 8–10 points clinically meaningful for all patients?
MCID estimates (8–10 points on total FACT-L, 3–4 on LCS) are derived from large cohorts but vary by baseline severity and disease trajectory. Deterioration in advanced cancer may be more clinically meaningful at lower thresholds; improvement in early-stage survivors at higher thresholds. Always contextualize MCID with clinical milestones (response, progression, toxicity, hospitalization).
How do I handle missing items in FACT-Lung scoring?
If 50% or more of items in a subscale are missing, that subscale is not scored. If fewer than 50% are missing, impute the subscale mean (average of completed items) and multiply by the full subscale item count. Avoid subscale interpretation if multiple consecutive items are missing (possible misunderstanding). Consult protocol-specific imputation rules for regulatory trials.
Does FACT-Lung include performance status or functional capacity assessment?
No. FACT-Lung is self-reported QoL, not objective performance status. Functional Well-Being subscale asks about work and daily activity limitations but does not grade ECOG status. Pair FACT-Lung with clinician-rated ECOG performance status (0–4 scale) or 6-minute walk test for comprehensive functional assessment.
What languages is FACT-Lung available in?
FACT-Lung has been validated in 40+ languages including Spanish, Mandarin, Japanese, German, French, Portuguese, Korean, Italian, Polish, Russian, and many others. Licensed translations are available through FACIT.org; ensure you use validated versions, not ad hoc machine translations, to preserve psychometric properties.
Sources
- Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995). Validation of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument for patients with lung cancer. J Clin Oncol, 13(1), 142–153. link ↗
- Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 11(3), 570–579. DOI: 10.1200/JCO.1993.11.3.570 ↗
How to cite this page
ScholarGate. (2026, June 3). Functional Assessment of Cancer Therapy—Lung. ScholarGate. https://scholargate.app/en/oncology/fact-lung
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cancer Worry ScaleOncology↔ compare
- EORTC QLQ-LC13Oncology↔ compare
- FACT-ColorectalOncology↔ compare
- FACT-OvarianOncology↔ compare
- FACT-ProstateOncology↔ compare